ESMO 2023 (Poster nr 1051P)
Intratumoral injection of LTX-315 in combination with Pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from from the ATLAS-IT-05 trial
Intratumoral injection of LTX-315 in combination with Pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from from the ATLAS-IT-05 trial
SITC 2022 (Poster nr 1126)
Molecular mechanisms of DC activation by melanoma cells responding to LTX-315
Molecular mechanisms of DC activation by melanoma cells responding to LTX-315
ASCO 2022 (11567)
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma (ATLAS-IT-04)
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma (ATLAS-IT-04)
SITC 2021 (Poster nr 560)
Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer
Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer
AACR 2019 (Poster nr 3274)
LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model
LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model
AACR 2019 (Poster nr CT069)
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
AACR 2019 (Poster nr CT010)
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
ASCO 2018 Poster (3094)
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
SITC 2017 (Poster Number 10)
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
SITC 2017 (Poster Number 250)
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
CIMT 2017 Poster 2
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment in the majority of patients with advanced metastatic tumors: Results from an ongoing clinical phase I study
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment in the majority of patients with advanced metastatic tumors: Results from an ongoing clinical phase I study
CIMT 2017 Poster 1
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
ASCO 2017 Poster
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
AACR 2017 Poster 4
Induction of immunogenic cell death and tumor regression in murine animal models by a novel cytolytic compound, LTX-401
Induction of immunogenic cell death and tumor regression in murine animal models by a novel cytolytic compound, LTX-401
AACR 2017 Poster 3
Mode of action study on LTX-315-induced cell death
Mode of action study on LTX-315-induced cell death
AACR 2017 Poster 2
A phase I, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumors (NCTO 1986426)
A phase I, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumors (NCTO 1986426)
AACR 2017 Poster 1
The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with chemotherapy
The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with chemotherapy
CIMT 2016 and BIO 2016 Poster
The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with CTLA-4 blockade
The oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with CTLA-4 blockade
AACR 2016 Poster 4
The amphiphatic ß(2,2)-amino acid LTX-401 induces complete regression of experimental hepatocellular carcinoma
The amphiphatic ß(2,2)-amino acid LTX-401 induces complete regression of experimental hepatocellular carcinoma
AACR 2016 Poster 3
The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin
The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin
AACR 2016 Poster 2
LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner
LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner
AACR 2016 Poster 1
Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody
Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody
ECC 2015 Poster 528
Intra-tumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces infiltration of CD8 effectors T-cells and regression in some injected tumors
Intra-tumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces infiltration of CD8 effectors T-cells and regression in some injected tumors
AACR 2015 Poster 24/13
Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore™) in combination with low-dose cyclophosphamide
Anticancer effects obtained against A20 lymphomas following treatment with LTX-315 (Oncopore™) in combination with low-dose cyclophosphamide
SITC 2014 Poster P264
Complete and specific regression of disseminated tumors in a novel rat mesenchymal three-tumor model after intralesional treatment with the nonapeptide LTX-315 (OncoporeTM)
Complete and specific regression of disseminated tumors in a novel rat mesenchymal three-tumor model after intralesional treatment with the nonapeptide LTX-315 (OncoporeTM)
ASCO 2014 Poster 3067
A Phase I study with LTX-315 - an immunogenic cell death inducer - in patients with transdermally accessible tumors
A Phase I study with LTX-315 - an immunogenic cell death inducer - in patients with transdermally accessible tumors
CIMT 2014 Poster
LTX-315 treatment induces complete and specific regression of dissaminated tumors in a novel mesenchymal three tumor mode
LTX-315 treatment induces complete and specific regression of dissaminated tumors in a novel mesenchymal three tumor mode
AACR 2013 Poster 474
Complete regression and long-term specific protective immune responses obtained in rodent tumor models after intratumoral treatment with LTX-315
Complete regression and long-term specific protective immune responses obtained in rodent tumor models after intratumoral treatment with LTX-315
AACR 2013 Poster 477
Long-term protection against B16F1 melanoma upon vaccination with tumor cell lysate combined with LTX-315 as a novel adjuvant
Long-term protection against B16F1 melanoma upon vaccination with tumor cell lysate combined with LTX-315 as a novel adjuvant
Poster AACR 2012
Complete regression of solid B16F1melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore®)
Complete regression of solid B16F1melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore®)